Research

Semaglutide Lifespan Mouse Study: What Nature Found

Nature study: semaglutide extended lifespan in older female mice and slowed aging hallmarks. Here's the evidence, the limits, and why it isn't human proof yet.

By PeptidesBeat Staff

Last reviewed September 3, 2026

Starting semaglutide late in life extended lifespan in healthy older female mice and tempered hallmarks of aging — but this is mouse data, and it is not evidence that a person should take Ozempic or Wegovy as an anti-aging drug. The results come from an NIH-funded study published Sept. 2, 2026, in Nature (Feng et al., DOI 10.1038/s41586-026-10940-7) and announced the same day by the NIH. Female C57BL/6 mice started on daily semaglutide at 20 months of age lived a median 834 days versus 742 days for controls — roughly 92 days longer in the paper, or “nearly 100 days longer” in the NIH’s accounting.

The limitation belongs in the same breath as the finding. This is one study, in one inbred mouse strain, in females only, at one dose and schedule, with treatment continued every day for the rest of the animals’ lives. It says nothing directly about human aging — and both the paper and the NIH release say so. The NIH notes the results “do not imply that similar results could be achieved immediately in humans,” and the authors write that testing whether the effect carries over will require long-term clinical studies designed to evaluate aging-related outcomes in older populations.

What makes the study worth attention is not the headline alone but the biology around it: semaglutide improved muscle, motor, and cognitive measures, restored features of a younger cellular state, and outperformed calorie restriction on several outcomes — findings the researchers read as evidence the drug works through more than appetite suppression. Here is what the study actually did, what it means for the “GLP-1 anti-aging” conversation, and where the evidence stops.

Does Ozempic slow aging? The short answer

Not proven in humans. No study has shown that semaglutide — the active ingredient in Ozempic and Wegovy — slows aging or extends lifespan in people, and aging is not an FDA-recognized indication for any GLP-1 drug. What the Sept. 2, 2026, Nature paper shows is a strong effect in one animal model: older female mice treated late in life lived longer and showed fewer hallmarks of aging. That is a hypothesis-generating result for human research, not a reason to take the drug for longevity. For that reason, every lifespan figure in this article is specifically a mouse figure.

What the Sept. 2, 2026 Nature study found

The study design

Researchers at UC Berkeley (corresponding author Danica Chen) gave semaglutide, a GLP-1 receptor agonist, to older, healthy female C57BL/6 mice beginning at 20 months of age — late in a mouse’s normal lifespan — as a daily subcutaneous injection of 10 nmol/kg. Treatment cut food intake by about 24%. One group stayed on semaglutide for the rest of life (40 treated versus 39 control animals) to measure lifespan; separate groups were treated for about three months and then assessed for muscle, motor, cognitive, and metabolic function. The work was funded by the National Institute on Aging (grants R01AG063404, R01AG063389, R01AG082105).

Lifespan and healthspan results

Median lifespan was 742 days in controls versus 834 days in semaglutide-treated mice — about 92 days longer per the paper, “nearly 100 days longer” per the NIH release, or roughly 12%. Death was delayed across several non-tumor categories, not by shifting one single cause.

In the three-month assessments, treated mice showed improved muscle and motor function, better spatial memory on the Barnes maze, more exploratory drive, and better glucose control. On the molecular side, the treatment tempered multiple hallmarks of aging: less inflammation and cellular senescence, less aging of hematopoietic and neural stem cells, restored neurogenesis in the dentate gyrus, less genomic instability, and better mitochondrial function and protein quality control. The pattern of molecular changes tracked calorie restriction — higher NAD+, induced sirtuins, lower IGF-1, induced Oser1 — which is exactly what the paper means when it describes semaglutide “supporting its function as a calorie restriction mimetic.”

Beyond calorie restriction: the mechanism question

Is semaglutide a calorie restriction mimetic?

Partly — with evidence it does more than make animals eat less. Because semaglutide reduced food intake by roughly a quarter, the team ran a head-to-head comparison against a matched 24% calorie-restricted diet (5 months, 10 mice per group) to separate drug effects from eating less.

Semaglutide matched calorie restriction on many measures but exceeded it on exploratory drive, spatial memory, and glucose tolerance — in some cases improving outcomes above baseline. Metabolic rate dropped in the calorie-restricted mice but stayed largely unchanged with semaglutide. “These differences point to the possibility that GLP-1 drugs tap into a biological pathway independent of calorie restriction,” Chen said in the NIH release. The practical caveat: whether semaglutide acts as a calorie-restriction mimetic — or something more — in humans is untested.

What this means for humans — and what it doesn’t

The honest translation of this study for a human reader is short: mice are not people, and this result does not tell you whether semaglutide slows human aging. Four design features make the leap especially hard. First, the cohort was females only — the authors chose females “to minimize confounding effects of male aggression and injury,” so males were not tested. Second, it is a single inbred strain, which narrows how far the result generalizes even among mice. Third, the regimen was specific: 10 nmol/kg/day subcutaneous semaglutide started at 20 months and continued to death. Fourth, the study was not designed as a safety assessment — the absence of adverse findings within the monitored endpoints is a study observation, not human safety evidence.

On the human side, the strongest evidence remains indirect. In meta-analyses of people with diabetes and obesity, GLP-1 drugs have been associated with lower mortality, and semaglutide’s SELECT cardiovascular-outcomes trial showed reduced heart events in a high-risk population — independent experts reviewing the mouse paper point to that human record while stressing that reducing mortality in a sick, high-risk group is not the same as slowing aging in healthy people (Science Media Centre expert reaction, Sept. 2, 2026). Randomized trials that treat aging itself as an outcome in older adults are the next step, and they have not been done.

Also not proven: that “longevity microdosing” programs selling low-dose semaglutide deliver the effects in this paper. No trial has tested microdosing for aging outcomes, and the mouse study’s dose and schedule do not map to any marketed human protocol. Semaglutide is approved for diabetes, cardiovascular risk reduction, and weight management in specific populations — not for aging. For context on the drug’s other effects, see our analysis of GLP-1’s effects beyond weight loss, including visceral fat and cardiovascular trial data. The same beyond-metabolism question now reaches respiratory medicine: at the ERS Congress 2026, a UK electronic-records study linked semaglutide to fewer asthma attacks and COPD flare-ups than sulfonylureas — observational and not peer-reviewed — see our coverage of semaglutide and the ERS 2026 asthma/COPD data.

GLP-1 anti-aging: separating the evidence from the hype

The “GLP-1 anti-aging” search space is crowded with clinics and wellness brands selling semaglutide as a longevity treatment, often with price tags and microdosing claims that run well ahead of the data. This Nature study is real evidence — but it is animal evidence, and the commercially useful version of the story (“take this and live longer”) is not what the study shows. The same gap between marketing and evidence applies to longevity-claimed peptides: research-grade compounds such as epitalon and MOTS-c are marketed with longevity narratives built on far thinner human data than semaglutide has, which cuts in the opposite direction — even the best-studied drug in the class has no human aging trial.

A balanced read also includes side effects and trade-offs. GLP-1 drugs cause real adverse effects — gastrointestinal symptoms, muscle loss in some patients, and signals flagged in 2026 research on hair loss with GLP-1 use — alongside emerging central-nervous-system signals worth watching. Any longevity framing that ignores those costs is incomplete. Muscle preservation is a particular concern for an anti-aging argument, since losing lean mass is the opposite of healthy aging; see our coverage of muscle loss on GLP-1 and weight-loss drugs.

Finally, follow the money: the University of California Regents have filed a patent application covering GLP-1 receptor agonists for healthy aging. Disclosures like that do not invalidate the science — they are context for reading it.

Frequently asked questions

Does Ozempic slow aging?

Not proven in humans. A Sept. 2, 2026 NIH-funded Nature study found that late-life semaglutide (the active ingredient in Ozempic and Wegovy) extended lifespan in healthy older female mice and tempered aging hallmarks — but it is mouse data, from females only, and is not evidence that Ozempic slows aging in people. Semaglutide is not approved for aging or longevity.

Did semaglutide extend lifespan in mice?

Yes, in this one study. Female C57BL/6 mice started on daily semaglutide at 20 months of age lived a median 834 days versus 742 days for controls — about 92 days longer per the paper, “nearly 100 days” per the NIH. Death was delayed across several non-tumor categories. Limits: a single inbred strain, females only, one dose, with treatment continued daily for life.

Is semaglutide a calorie restriction mimetic?

Partly. Semaglutide cut food intake about 24%, and most outcomes tracked a matched 24% calorie-restricted diet. But treated mice beat the calorie-restricted group on spatial memory, exploratory drive, and glucose tolerance, with metabolism largely unchanged — pointing to effects beyond eating less. Whether that extends to humans is untested.

Can I take Ozempic or Wegovy for longevity?

No approved use exists. Aging is not an FDA-recognized indication, and neither Ozempic nor Wegovy is approved as an anti-aging or longevity drug. The mouse study is not a basis for human use, and “longevity microdosing” programs are not supported by clinical trials. Talk to a licensed prescriber about any medically appropriate use; never start, stop, or change a medication on your own.

Sources

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.